Praecis Puts Brakes On Plenaxis, Explores Strategic Financing Options
This article was originally published in The Pink Sheet Daily
Company will record $7.5 mil. in charges after announcing it will not enter a licensing or sale transaction for the prostate cancer therapy.
You may also be interested in...
Latest deal could bring GSK’s total price tag for December to almost $4 billion.
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13